Tazemetostat is a small molecule inhibitor of EZH2 histone methyltransferase activity that reduces H3K27 trimethylation (H3K27me3) levels and targets the epigenetic silencing of tumor suppressor genes and other genes involved in the development of NHL-type B-cell malignancies associated with oncogenesis [5, 6]. This evidence concerns the gene EZH2 and non-Hodgkin lymphoma.